Contract Research Organizations
•37 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (37)
| Company | Market Cap | Price |
|---|---|---|
|
TMO
Thermo Fisher Scientific Inc.
Thermo Fisher provides contract research organization services (CRO capabilities) for outsourced drug development.
|
$219.06B |
$582.78
+0.46%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$38.00B |
$222.94
-0.27%
|
|
LH
Labcorp Holdings Inc.
Labcorp functions as aContract Research Organization offering outsourced drug development and regulatory support services.
|
$22.26B |
$267.69
-0.07%
|
|
MEDP
Medpace Holdings, Inc.
Medpace's core business is a specialized full-service CRO delivering Phase I–IV clinical development services.
|
$16.61B |
$594.74
+0.58%
|
|
ICLR
ICON Public Limited Company
Directly describes ICON's outsourced drug development and management services as a Contract Research Organization.
|
$13.49B |
$162.46
-0.61%
|
|
CRL
Charles River Laboratories International, Inc.
CRL operates as a contract research organization, outsourcing preclinical drug development services.
|
$8.33B |
$167.59
-0.96%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$5.56B |
$116.87
-0.15%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$1.88B |
$4.26
-1.50%
|
|
AZTA
Azenta, Inc.
Genewiz genomic sequencing and broader SMS/Multiomics services align with Contract Research Organizations.
|
$1.37B |
$30.01
+0.44%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$919.80M |
$10.49
+2.69%
|
|
FLGT
Fulgent Genetics, Inc.
Contract Research Organization services for bioPharma.
|
$905.72M |
$28.98
-2.06%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Contract Research Organizations as a historic and current service model.
|
$473.60M |
$8.14
+1.81%
|
|
CLPT
ClearPoint Neuro, Inc.
Biologics and drug-delivery consulting capabilities (GLP expansion, preclinical support) align with CRO-like outsourced development services.
|
$440.62M |
$15.69
+1.23%
|
|
ABSI
Absci Corporation
Partnership-driven model for drug creation aligns with Contract Research Organizations (CRO)-like outsourced R&D services.
|
$421.65M |
$2.90
+9.66%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore's development pipeline and development services align with Contract Research Organizations.
|
$292.13M |
$7.96
+0.95%
|
|
ACRS
Aclaris Therapeutics, Inc.
The company reports contract research revenue, indicating provided drug development services.
|
$251.33M |
$2.56
+10.56%
|
|
QTRX
Quanterix Corporation
Offers contract research services via its Accelerator Lab, aligning with CRO-type activities.
|
$247.20M |
$5.67
+6.67%
|
|
IMRX
Immuneering Corporation
The company relies on contract research organizations for preclinical/clinical testing and trials.
|
$234.26M |
$6.28
-2.64%
|
|
MXCT
MaxCyte, Inc.
Contract Research Organizations tag reflects MaxCyte's CRO-like gene editing assessment services through SeQure Dx.
|
$168.44M |
$1.60
+6.29%
|
|
BNR
Burning Rock Biotech Limited
Biopharma services segment indicates outsourced R&D, clinical testing, and development support.
|
$116.85M |
$11.86
+4.73%
|
|
CSBR
Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
|
$95.06M |
$6.75
-2.25%
|
|
FBIO
Fortress Biotech, Inc.
Fortress engages in outsourced development activities and governance across its portfolio, aligning with CRO services.
|
$77.47M |
$2.60
+4.62%
|
|
ABVC
ABVC BioPharma, Inc.
BioKey provides Contract Research Organization services, including API characterization, formulation development, and regulatory submissions.
|
$65.92M |
$2.92
+4.46%
|
|
AKYA
Akoya Biosciences, Inc.
Contract Research Organizations alignment due to outsourced lab services and clinical testing capabilities.
|
$64.26M |
$1.29
|
|
BDSX
Biodesix, Inc.
Biodesix's Development Services revenue aligns with CRO-like outsourced diagnostic testing for partners.
|
$57.92M |
$8.18
+3.54%
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$42.98M |
$1.24
-1.20%
|
|
VNRX
VolitionRx Limited
Nu.Q Discover provides epigenetic profiling services to drug developers, akin to Contract Research Organizations.
|
$36.52M |
$0.34
-4.01%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$36.07M |
$1.03
-1.43%
|
|
PLUR
Pluri Inc.
Contract research and development services complement CDMO capabilities and scale the pipeline.
|
$32.74M |
$3.98
-4.78%
|
|
RADX
Radiopharm Theranostics Limited
Company provides external development services for others, akin to CRO activities.
|
$29.97M |
$4.71
+3.74%
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
|
$9.42M |
$1.01
+1.00%
|
|
SEED
Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
|
$8.81M |
$1.42
+2.16%
|
|
APM
Aptorum Group Limited
Aptorum plans near-term revenue from biopharma services via the DiamiR merger, aligning with contract research/Development outsourcing.
|
$7.77M |
$1.41
-1.06%
|
|
BUDZ
WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
|
$5.44M |
$0.04
|
|
POAI
Predictive Oncology Inc.
Provides outsourced drug discovery services (wet lab, testing, and preclinical support) akin to a CRO.
|
$3.87M |
$6.38
-1.92%
|
|
YBGJ
Yubo International Biotech Limited
Provides outsourced research/testing services and advisory functions (CRO-like capabilities).
|
$2.48M |
$0.01
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$2.17M |
$5.44
-1.27%
|
Loading company comparison...
Loading industry trends...
Loading research report...
